166 related articles for article (PubMed ID: 36015284)
1. Comparison of the Blood-Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug-Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging.
Breuil L; Goutal S; Marie S; Del Vecchio A; Audisio D; Soyer A; Goislard M; Saba W; Tournier N; Caillé F
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015284
[TBL] [Abstract][Full Text] [Related]
2. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
[TBL] [Abstract][Full Text] [Related]
3. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function.
Goutal S; Novell A; Leterrier S; Breuil L; Selingue E; Gerstenmayer M; Marie S; Saubaméa B; Caillé F; Langer O; Truillet C; Larrat B; Tournier N
J Control Release; 2023 Sep; 361():483-492. PubMed ID: 37562557
[TBL] [Abstract][Full Text] [Related]
4. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
[TBL] [Abstract][Full Text] [Related]
6. Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [
Breuil L; Ziani N; Leterrier S; Hugon G; Caillé F; Bouilleret V; Truillet C; Goislard M; El Biali M; Bauer M; Langer O; Goutal S; Tournier N
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559144
[TBL] [Abstract][Full Text] [Related]
7. [
Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
[TBL] [Abstract][Full Text] [Related]
8. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
9. Parametric Imaging of P-Glycoprotein Function at the Blood-Brain Barrier Using k
Breuil L; El Biali M; Vodovar D; Marie S; Auvity S; Bauer M; Goutal S; Rodrigo S; Langer O; Tournier N
Mol Imaging Biol; 2023 Dec; 25(6):1135-1141. PubMed ID: 37801196
[TBL] [Abstract][Full Text] [Related]
10. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
[TBL] [Abstract][Full Text] [Related]
11. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
12. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
13. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
14. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
15. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate
Tournier N; Bauer M; Pichler V; Nics L; Klebermass EM; Bamminger K; Matzneller P; Weber M; Karch R; Caillé F; Auvity S; Marie S; Jäger W; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Jul; 60(7):985-991. PubMed ID: 30630940
[TBL] [Abstract][Full Text] [Related]
16. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
17. Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide.
Caillé F; Goutal S; Marie S; Auvity S; Cisternino S; Kuhnast B; Pottier G; Tournier N
Contrast Media Mol Imaging; 2018; 2018():7310146. PubMed ID: 29853808
[TBL] [Abstract][Full Text] [Related]
18. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
[TBL] [Abstract][Full Text] [Related]
20. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux.
Zoghbi SS; Liow JS; Yasuno F; Hong J; Tuan E; Lazarova N; Gladding RL; Pike VW; Innis RB
J Nucl Med; 2008 Apr; 49(4):649-56. PubMed ID: 18344435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
